We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Odyssey Pharmaceuticals and Indevus Pharmaceuticals have announced that Odyssey
plans to initiate this month a Phase IV study of the effectiveness and safety
of Sanctura in patients with overactive bladder (OAB) symptoms.
Viragen's anticancer product, the anti-CD55 antibody, was found to significantly
enhance the activity of Rituxan when both drugs were used together in a cell-based
evaluation study.
Exelixis has initiated a Phase I clinical trial to evaluate the safety, tolerability
and pharmacokinetic profile of XL880, a novel, orally administered, small molecule
anticancer compound.
Targeted Genetics has reported that its Phase II clinical trial of tgAAVCF in
patients with mild-to-moderate cystic fibrosis (CF) failed to meet its primary
endpoint of statistically significant improvement in lung function, 30 days
following initial administration of tgAAVCF compared to placebo.
Corautus Genetics has selected PPD to provide certain clinical research services
for GENASIS (Genetic Angiogenic Stimulation Investigational Study), Corautus'
Phase IIb clinical trial to evaluate the safety and efficacy of vascular endothelial
growth factor-2 for the treatment of patients with severe angina.
Cystic Fibrosis Foundation Therapeutics (CFFT), the drug discovery and development
affiliate of the Cystic Fibrosis Foundation, and Alnylam Pharmaceuticals, a
leading RNAi therapeutics company, have initiated a collaborative program to
discover Direct RNAi therapeutics for the treatment of cystic fibrosis (CF).
Hana Biosciences has announced positive results of a pilot pharmacokinetic clinical
trial that was conducted using its proprietary lingual spray version of ondansetron
HCl (the active ingredient marketed under the brand name Zofran by GlaxoSmithKline)
for the treatment of chemotherapy-induced nausea and vomiting.